Objective： To observe the regulation of Chinese herbal medicine, Modified Qing＇e Pill（加味青娥丸, MQEP）, on the expression of adiponectin, bone morphogenetic protein 2（BMP2）, osteoprotegerin（OPG） and other pot...Objective： To observe the regulation of Chinese herbal medicine, Modified Qing＇e Pill（加味青娥丸, MQEP）, on the expression of adiponectin, bone morphogenetic protein 2（BMP2）, osteoprotegerin（OPG） and other potentially relevant risk factors in patients with nontraumatic osteonecrosis of the femoral head（ONFH）. Methods： A total of 96 patients with nontraumatic ONFH were unequal randomly divided into treatment group（60 cases） and control group（36 cases）. The treatment group were treated with MQEP while the control group were treated with simulated pills. Both groups were given caltrate D. Six months were taken as a treatment course. Patients were followed up every 2 months. The levels of plasma adiponectin, BMP2, OPG, von Willebrand factor（vWF）, von Willebrand factor cleaving protease（vWF-cp）, plasminogen activator inhibitor 1（PAI-1）, tissue plasminogen activator（tPA）, C-reactive protein（CRP）, blood rheology, bone mineral density（BMD） of the femoral head and Harris Hip Score were measured before and after treatment. Results： After 6 months of treatment, compared with the control group, patients in the treatment group had significantly higher adiponectin and BMP2 levels（P〈0.01 and P=0.013, respectively）, lower vWF, PAI-1 and CRP levels（P=0.019, P〈0.01 and P〈0.01, respectively）, and lower blood rheology parameters. BMD of the femoral neck, triangle area and Harris Hip Score in the treatment group were significantly higher than those in the control group. Moreover, plasma adiponectin showed a positive association with BMP2（r=0.231, P=0.003） and a negative association with PAI-1（r=–0.159, P〈0.05）. Conclusions： MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin, regulating bone metabolism and improving the hypercoagulation state, which may provide an experimental base for its clinical effects.展开更多
目的研究BAMBI基因在小鼠不同脂肪组织发育过程中的表达规律。方法利用RT-q PCR及Western blot技术检测BAMBI基因在小鼠不同类型脂肪组织、不同发育阶段(胚胎第18天、出生第0天、第21天、第8周和第6个月)及原代前体脂肪细胞分化过程中(...目的研究BAMBI基因在小鼠不同脂肪组织发育过程中的表达规律。方法利用RT-q PCR及Western blot技术检测BAMBI基因在小鼠不同类型脂肪组织、不同发育阶段(胚胎第18天、出生第0天、第21天、第8周和第6个月)及原代前体脂肪细胞分化过程中(分化第0、3、7、11天)的差异表达情况。结果随着脂肪组织的发育,BAMBI m RNA及蛋白的表达量逐渐降低;在发育的同一时间段,BAMBI m RNA在内脏白色脂肪组织较皮下白色脂肪组织表达量高,在棕色脂肪组织中表达量最低;在小鼠前体脂肪细胞诱导分化过程中,BAMBI m RNA表达量呈时间依赖性降低。结论提示BAMBI的差异表达规律与脂肪组织类型、发育阶段以及脂肪细胞分化程度密切相关,其在脂肪组织发育过程中起着重要的作用。展开更多
目的探讨骨形态发生蛋白9(BMP-9)在胆道闭锁(BA)肝纤维化中的作用机制。方法选取14例BA患儿肝组织标本为BA组,5例胆总管囊肿(CBD)患儿肝组织标本为CBD组,HE染色对肝组织进行肝纤维化评估,免疫组化染色检测BMP-9、p-SMAD1/5表达情况,实...目的探讨骨形态发生蛋白9(BMP-9)在胆道闭锁(BA)肝纤维化中的作用机制。方法选取14例BA患儿肝组织标本为BA组,5例胆总管囊肿(CBD)患儿肝组织标本为CBD组,HE染色对肝组织进行肝纤维化评估,免疫组化染色检测BMP-9、p-SMAD1/5表达情况,实时荧光定量逆转录聚合酶链反应(qPCR)检测肝组织BMP-9及DNA结合抑制因子1(ID1)mRNA表达水平。培养人肝星状细胞LX-2,用重组转化生长因子(rTGF)-β1与重组BMP(r BMP)-9处理,蛋白质印迹法检测细胞中SMAD1/5、p-SMAD1/5、ID1蛋白及α-平滑肌肌动蛋白(α-SMA)表达情况,qPCR检测细胞中α-SMA及ID1 mRNA表达情况。结果BA组肝组织中BMP-9及p-SMAD1/5蛋白、BMP-9及ID1mRNA表达水平均高于CBD组;在BA组中重度肝纤维化患儿BMP-9蛋白、BMP-9及ID1 m RNA的表达高于轻度肝纤维化患儿(P<0.05)。LX-2细胞经rTGF-β1、rBMP-9处理后,α-SMA蛋白及α-SMA m RNA表达水平均升高(P<0.05)。LX-2细胞加入不同剂量rBMP-9之后,其下游通路中p-SMAD1/5、SMAD1/5、ID1、α-SMA蛋白,及ID1、α-SMAmRNA表达均较0μg/L组升高(P<0.05)。结论在BA患儿肝组织中BMP-9、p-SMAD1/5、ID1表达水平较CBD患儿增高,与肝纤维化严重程度有关。BMP-9可通过SMAD/ID1信号通路激活人肝星状细胞LX-2,促进纤维化进程。展开更多
目的:探讨sh RNA干扰骨形成蛋白和激活素的穿膜抑制剂(bone morphogenetic protein and activin membrane bound inhibitor,BAMBI)基因对人结肠癌SW480细胞增殖、凋亡、侵袭和迁移的影响及其作用机制。方法:转染SW480细胞sh-BAMBI成功后...目的:探讨sh RNA干扰骨形成蛋白和激活素的穿膜抑制剂(bone morphogenetic protein and activin membrane bound inhibitor,BAMBI)基因对人结肠癌SW480细胞增殖、凋亡、侵袭和迁移的影响及其作用机制。方法:转染SW480细胞sh-BAMBI成功后,实时定量PCR(q RT-PCR)和Western blotting检测BAMBI m RNA和蛋白表达水平,MTT法检测SW480细胞增殖能力,Hoechst33258染色检测细胞凋亡情况,Transwell实验检测细胞侵袭能力,划痕实验检测SW480细胞迁移能力,Western blotting检测TGF-β/Smad2通路相关蛋白的表达水平。结果:转染成功后sh-BAMBI组中BAMBI的m RNA和蛋白水平均低于对照组(P<0.05);与对照组相比,sh-BAMBI组细胞增殖率明显降低(P<0.05)、细胞凋亡率显著升高(P<0.01),同时其侵袭和迁移能力明显减弱(均P<0.05)。sh-BAMBI组TGF-β蛋白水平和p-Smad2/Smad2比值明显高于对照组(P<0.05)。结论:sh RNA干扰BAMBI可诱导人结肠癌SW480细胞凋亡并抑制细胞增殖、侵袭和迁移,其机制可能与激活TGFβ/Smad2通路有关。展开更多
基金Supported by the National Natural Science Foundation of China(No.81273907)
文摘Objective： To observe the regulation of Chinese herbal medicine, Modified Qing＇e Pill（加味青娥丸, MQEP）, on the expression of adiponectin, bone morphogenetic protein 2（BMP2）, osteoprotegerin（OPG） and other potentially relevant risk factors in patients with nontraumatic osteonecrosis of the femoral head（ONFH）. Methods： A total of 96 patients with nontraumatic ONFH were unequal randomly divided into treatment group（60 cases） and control group（36 cases）. The treatment group were treated with MQEP while the control group were treated with simulated pills. Both groups were given caltrate D. Six months were taken as a treatment course. Patients were followed up every 2 months. The levels of plasma adiponectin, BMP2, OPG, von Willebrand factor（vWF）, von Willebrand factor cleaving protease（vWF-cp）, plasminogen activator inhibitor 1（PAI-1）, tissue plasminogen activator（tPA）, C-reactive protein（CRP）, blood rheology, bone mineral density（BMD） of the femoral head and Harris Hip Score were measured before and after treatment. Results： After 6 months of treatment, compared with the control group, patients in the treatment group had significantly higher adiponectin and BMP2 levels（P〈0.01 and P=0.013, respectively）, lower vWF, PAI-1 and CRP levels（P=0.019, P〈0.01 and P〈0.01, respectively）, and lower blood rheology parameters. BMD of the femoral neck, triangle area and Harris Hip Score in the treatment group were significantly higher than those in the control group. Moreover, plasma adiponectin showed a positive association with BMP2（r=0.231, P=0.003） and a negative association with PAI-1（r=–0.159, P〈0.05）. Conclusions： MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin, regulating bone metabolism and improving the hypercoagulation state, which may provide an experimental base for its clinical effects.
文摘目的研究BAMBI基因在小鼠不同脂肪组织发育过程中的表达规律。方法利用RT-q PCR及Western blot技术检测BAMBI基因在小鼠不同类型脂肪组织、不同发育阶段(胚胎第18天、出生第0天、第21天、第8周和第6个月)及原代前体脂肪细胞分化过程中(分化第0、3、7、11天)的差异表达情况。结果随着脂肪组织的发育,BAMBI m RNA及蛋白的表达量逐渐降低;在发育的同一时间段,BAMBI m RNA在内脏白色脂肪组织较皮下白色脂肪组织表达量高,在棕色脂肪组织中表达量最低;在小鼠前体脂肪细胞诱导分化过程中,BAMBI m RNA表达量呈时间依赖性降低。结论提示BAMBI的差异表达规律与脂肪组织类型、发育阶段以及脂肪细胞分化程度密切相关,其在脂肪组织发育过程中起着重要的作用。
文摘目的探讨骨形态发生蛋白9(BMP-9)在胆道闭锁(BA)肝纤维化中的作用机制。方法选取14例BA患儿肝组织标本为BA组,5例胆总管囊肿(CBD)患儿肝组织标本为CBD组,HE染色对肝组织进行肝纤维化评估,免疫组化染色检测BMP-9、p-SMAD1/5表达情况,实时荧光定量逆转录聚合酶链反应(qPCR)检测肝组织BMP-9及DNA结合抑制因子1(ID1)mRNA表达水平。培养人肝星状细胞LX-2,用重组转化生长因子(rTGF)-β1与重组BMP(r BMP)-9处理,蛋白质印迹法检测细胞中SMAD1/5、p-SMAD1/5、ID1蛋白及α-平滑肌肌动蛋白(α-SMA)表达情况,qPCR检测细胞中α-SMA及ID1 mRNA表达情况。结果BA组肝组织中BMP-9及p-SMAD1/5蛋白、BMP-9及ID1mRNA表达水平均高于CBD组;在BA组中重度肝纤维化患儿BMP-9蛋白、BMP-9及ID1 m RNA的表达高于轻度肝纤维化患儿(P<0.05)。LX-2细胞经rTGF-β1、rBMP-9处理后,α-SMA蛋白及α-SMA m RNA表达水平均升高(P<0.05)。LX-2细胞加入不同剂量rBMP-9之后,其下游通路中p-SMAD1/5、SMAD1/5、ID1、α-SMA蛋白,及ID1、α-SMAmRNA表达均较0μg/L组升高(P<0.05)。结论在BA患儿肝组织中BMP-9、p-SMAD1/5、ID1表达水平较CBD患儿增高,与肝纤维化严重程度有关。BMP-9可通过SMAD/ID1信号通路激活人肝星状细胞LX-2,促进纤维化进程。
